Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
BioProcess Internation...BioProcess International US West
Not Confirmed
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
09-11 March, 2026
Not Confirmed
Not Confirmed
09-11 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioProcess International US West
Not Confirmed
Contact SupplierBioProcess International US West
BioProcess Internation...BioProcess International US West
Industry Trade Show
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
09-11 March, 2026
Industry Trade Show
Not Confirmed
09-11 March, 2026
Digital content
NEWS #PharmaBuzz
24 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260224844659/en/Exelixis-to-Webcast-Fireside-Chats-as-Part-of-Upcoming-Investor-Conferences-in-March
10 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260210781065/en/Exelixis-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-Corporate-Update
02 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260130221586/en/Exelixis-Announces-U.S.-FDA-Accepted-the-New-Drug-Application-for-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-for-Patients-with-Metastatic-Colorectal-Cancer
27 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260127808059/en/Exelixis-to-Release-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-on-Tuesday-February-10-2026
16 Jan 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com//www.fiercepharma.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us
11 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260111609689/en/Exelixis-Announces-Preliminary-Fiscal-Year-2025-Financial-Results-Provides-2026-Financial-Guidance-and-Outlines-Key-Priorities-and-Milestones-for-2026
Drugs in Development
Details:
XL092 (Zanzalintinib) is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of meningioma.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: XL092
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2026
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Details : XL092 (Zanzalintinib) is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of meningioma.
Product Name : XL092
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2026
Details:
The collaboration aims to advance the clinical development of Zanzalintinib for colo-rectal cancer by targeting AXL, MerTK, VEGFR1, and c-Met.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: XL092
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Natera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2026
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Natera
Deal Size : Undisclosed
Deal Type : Collaboration
Exelixis, Natera Collaborate on Phase 3 Trial of Zanzalintinib for Colorectal Cancer
Details : The collaboration aims to advance the clinical development of Zanzalintinib for colo-rectal cancer by targeting AXL, MerTK, VEGFR1, and c-Met.
Product Name : XL092
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2026
Details:
XL-092 (Zanzalintinib) is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Soft-Tissue Sarcoma.
Lead Product(s): Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area: Oncology Brand Name: XL-092
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: The University of Texas MD Anderson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2025
Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : The University of Texas MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XL-092 (Zanzalintinib) is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Soft-Tissue Sarcoma.
Product Name : XL-092
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2025
Details:
Belzutifan is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Belzutifan,Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Recipient: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2025
Lead Product(s) : Belzutifan,Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Belzutifan is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2025
Details:
Durvalumab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Lead Product(s): Durvalumab,Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Exelixis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2025
Lead Product(s) : Durvalumab,Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Inapplicable
Deal Type : Inapplicable
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Details : Durvalumab is an antibody candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 07, 2025
Details:
Zanzalintinib in Men With Aggressive Variant Prostate Cancer is a small molecule drug candidate, which is currently being evaluated in Phase II studies for the treatment of Prostatic Neoplasms.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Deepak Kilari | Medical College of Wisconsin
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2025
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Deepak Kilari | Medical College of Wisconsin
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
Details : Zanzalintinib in Men With Aggressive Variant Prostate Cancer is a small molecule drug candidate, which is currently being evaluated in Phase II studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2025
Details:
Zanzalintinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bone Neoplasms.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: MD Anderson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2025
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Details : Zanzalintinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bone Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2025
Details:
Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: MD Anderson Cancer Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2025
Lead Product(s) : Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2025
Details:
Encoberminogene Rezmadenovec is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Transitional Cell.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Sponsor: Advent Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2025
Lead Product(s) : Encoberminogene Rezmadenovec
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Advent Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Details : Encoberminogene Rezmadenovec is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Transitional Cell.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 22, 2025
Details:
Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an ADC.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Antibody-drug Conjugate
Recipient: Adagene Suzhou Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 16, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Adagene Suzhou Limited
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis
Details : Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an ADC.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
September 16, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Dosage Form : CAPSULE;ORAL
Brand Name : COMETRIQ
Dosage Strength : EQ 20MG BASE
Packaging :
Approval Date : 2012-11-29
Application Number : 203756
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : CAPSULE;ORAL
Brand Name : COMETRIQ
Dosage Strength : EQ 80MG BASE
Packaging :
Approval Date : 2012-11-29
Application Number : 203756
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : CABOMETYX
Dosage Strength : EQ 20MG BASE
Packaging :
Approval Date : 2016-04-25
Application Number : 208692
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : CABOMETYX
Dosage Strength : EQ 40MG BASE
Packaging :
Approval Date : 2016-04-25
Application Number : 208692
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : CABOMETYX
Dosage Strength : EQ 60MG BASE
Packaging :
Approval Date : 2016-04-25
Application Number : 208692
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Share 
